Michael Liebowitz

Summary

Publications

  1. ncbi Response versus remission in obsessive-compulsive disorder
    Helen Blair Simpson
    New York State Psychiatric Institute, New York, NY 10032, USA
    J Clin Psychiatry 67:269-76. 2006
  2. doi Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial
    Michael Liebowitz
    Department of Psychiatry, Columbia University, New York, New York 10128, USA
    Depress Anxiety 27:964-76. 2010
  3. ncbi A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute, New York, NY 10032, USA
    J Clin Psychiatry 66:238-47. 2005
  4. ncbi A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder
    Michael R Liebowitz
    Department of Psychiatry, Columbia University, New York, NY 10025, USA
    J Clin Psychiatry 70:550-61. 2009
  5. ncbi Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute, New York 10032, USA
    Arch Gen Psychiatry 62:190-8. 2005
  6. ncbi A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder
    Michael R Liebowitz
    Department of Psychiatry, Columbia University, New York, NY, USA
    J Clin Psychiatry 68:1663-72. 2007
  7. ncbi Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
    Michael R Liebowitz
    Columbia University, New York, NY 10128, USA
    Curr Med Res Opin 24:1877-90. 2008
  8. ncbi A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute and Columbia University, New York 10032, USA
    J Clin Psychiatry 63:66-74. 2002
  9. ncbi Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings
    Franklin R Schneier
    Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, NY 10032, USA
    Depress Anxiety 25:1-7. 2008
  10. ncbi Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study
    Michael R Liebowitz
    New York State Psychiatric Institute, New York, NY, USA
    J Clin Psychiatry 64:785-92. 2003

Research Grants

  1. PHARMACOTHERAPY OF SOCIAL PHOBIA
    Michael Liebowitz; Fiscal Year: 2001
  2. CBT AUGMENTATION OF SRI PHARMACOTHERAPY FOR OCD
    Michael Liebowitz; Fiscal Year: 2004
  3. PHARMACOTHERAPY OF SOCIAL PHOBIA
    Michael Liebowitz; Fiscal Year: 1992
  4. CBT Augmentation of Paroxetine for Social Anxiety
    Michael Liebowitz; Fiscal Year: 2006

Detail Information

Publications51

  1. ncbi Response versus remission in obsessive-compulsive disorder
    Helen Blair Simpson
    New York State Psychiatric Institute, New York, NY 10032, USA
    J Clin Psychiatry 67:269-76. 2006
    ..To investigate rates of response and remission in adults with obsessive-compulsive disorder (OCD) after 12 weeks of evidence-based treatment...
  2. doi Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial
    Michael Liebowitz
    Department of Psychiatry, Columbia University, New York, New York 10128, USA
    Depress Anxiety 27:964-76. 2010
    ....
  3. ncbi A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute, New York, NY 10032, USA
    J Clin Psychiatry 66:238-47. 2005
    ..This double-blind study evaluated the anxiolytic efficacy, safety, and tolerability of venlafaxine extended release (ER) in adult out-patients with generalized social anxiety disorder...
  4. ncbi A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder
    Michael R Liebowitz
    Department of Psychiatry, Columbia University, New York, NY 10025, USA
    J Clin Psychiatry 70:550-61. 2009
    ..To evaluate the efficacy, safety, and tolerability of venlafaxine extended release (ER) in short-term treatment of panic disorder...
  5. ncbi Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute, New York 10032, USA
    Arch Gen Psychiatry 62:190-8. 2005
    ..Evidence indicates that venlafaxine hydrochloride extended release (ER) effectively ameliorates anxiety symptoms...
  6. ncbi A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder
    Michael R Liebowitz
    Department of Psychiatry, Columbia University, New York, NY, USA
    J Clin Psychiatry 68:1663-72. 2007
    ..This study evaluated the efficacy and tolerability of desvenlafaxine succinate (desvenlafaxine) in the treatment of major depressive disorder (MDD)...
  7. ncbi Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder
    Michael R Liebowitz
    Columbia University, New York, NY 10128, USA
    Curr Med Res Opin 24:1877-90. 2008
    ..To assess the efficacy, safety, and tolerability of 50- and 100-mg/day doses of desvenlafaxine (administered as desvenlafaxine succinate), a serotonin-norepinephrine reuptake inhibitor, for the treatment of major depressive disorder (MDD)...
  8. ncbi A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute and Columbia University, New York 10032, USA
    J Clin Psychiatry 63:66-74. 2002
    ..This multicenter, double-blind, placebo-controlled study was carried out to determine the effectiveness and safety of various daily dosages of paroxetine for the treatment of generalized social anxiety disorder...
  9. ncbi Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings
    Franklin R Schneier
    Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, NY 10032, USA
    Depress Anxiety 25:1-7. 2008
    ..Prior findings of decreased D(2) receptor availability in noncomorbid OCD were not confirmed. Decreased D(2) receptor availability was also associated with trait detachment, supporting prior findings in samples of healthy subjects...
  10. ncbi Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study
    Michael R Liebowitz
    New York State Psychiatric Institute, New York, NY, USA
    J Clin Psychiatry 64:785-92. 2003
    ..The goal of the current study was to evaluate the efficacy and tolerability of sertraline for the treatment of severe generalized social anxiety disorder in adults...
  11. ncbi Item-by-item factor analysis of the Yale-Brown Obsessive Compulsive Scale Symptom Checklist
    Suzanne B Feinstein
    Department of Psychiatry, New York State Psychiatric Institute, New York, New York, USA
    J Neuropsychiatry Clin Neurosci 15:187-93. 2003
    ..If replicated on a larger scale, the finding of new subtype groupings would have important implications for future research in obsessive-compulsive disorder...
  12. ncbi Citalopram treatment of social anxiety disorder with comorbid major depression
    Franklin R Schneier
    Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York 10032, USA
    Depress Anxiety 17:191-6. 2003
    ..The overlap of social anxiety disorder with atypical features of depression may primarily be due to the shared feature of rejection sensitivity...
  13. doi A double-masked, placebo-controlled study of fluoxetine for hypochondriasis
    Brian A Fallon
    New York State Psychiatric Institute, Manhattan, NY, USA
    J Clin Psychopharmacol 28:638-45. 2008
    ..Fluoxetine was well tolerated, with no significant differences in discontinuation due to side effects between treatment groups. Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis...
  14. pmc A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder
    Carlos Blanco
    Department of Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr, Box 69, New York, NY 10032, USA
    Arch Gen Psychiatry 67:286-95. 2010
    ..Medication and cognitive behavioral treatment are the best-established treatments for social anxiety disorder, yet many individuals remain symptomatic after treatment...
  15. ncbi Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder
    Yujuan Choy
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York 10019, USA
    Depress Anxiety 25:230-40. 2008
    ..They also suggest that Western clinicians should assess patients with social anxiety for features of offensive TKS, and they support further consideration of integrating TKS features into conceptualizations of social anxiety disorder...
  16. ncbi Integrating neurobiology and psychopathology into evidence-based treatment of social anxiety disorder
    Michael R Liebowitz
    Anxiety Disorders Clinic, New York State Psychiatric Institute, New York City, USA
    CNS Spectr 10:suppl13 1-11; discussion 12-3; quiz 14-5. 2005
    ..The prevalence, rates of recognition and treatment, patterns of comorbidity, quality-of-life issues, and natural history of SAD are discussed as well as pharmacologic and psychosocial treatment strategies for SAD...
  17. ncbi Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder
    Edna B Foa
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA
    Am J Psychiatry 162:151-61. 2005
    ..Serotonin reuptake inhibitors (SRIs) and cognitive behavior therapy by exposure and ritual prevention are both established treatments for OCD, yet their relative and combined efficacy have not been demonstrated conclusively...
  18. ncbi A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults
    Randall D Marshall
    New York State Psychiatric Institute, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
    Depress Anxiety 24:77-84. 2007
    ..Paroxetine was well tolerated and superior to placebo in ameliorating the symptoms of chronic PTSD, associated features of PTSD, dissociative symptoms, and interpersonal problems in the first trial conducted primarily in minority adults...
  19. ncbi Fluoxetine in children and adolescents with OCD: a placebo-controlled trial
    Michael R Liebowitz
    New York State Psychiatric Institute, Department of Psychiatry, Columbia University, New York 10032, USA
    J Am Acad Child Adolesc Psychiatry 41:1431-8. 2002
    ..To examine the safety and efficacy of fluoxetine in child and adolescent obsessive-compulsive disorder (OCD)...
  20. ncbi Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder
    H Blair Simpson
    New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    Depress Anxiety 19:225-33. 2004
    ..The CMI relapse rate was lower than previously reported. Nonetheless, responders receiving intensive EX/RP with or without CMI fared significantly better 12 weeks after treatment discontinuation than responders receiving CMI alone...
  21. ncbi Statistical choices can affect inferences about treatment efficacy: a case study from obsessive-compulsive disorder research
    Helen Blair Simpson
    Department of Psychiatry, Columbia University, USA
    J Psychiatr Res 42:631-8. 2008
    ..The use of appropriate statistical methods in psychiatric trials can advance public health by ensuring that valid inferences are made about treatment efficacy...
  22. ncbi The Liebowitz social anxiety scale for children and adolescents: an initial psychometric investigation
    Carrie Masia-Warner
    New York University School of Medicine, Child Study Center, New York, NY 10016, USA
    J Am Acad Child Adolesc Psychiatry 42:1076-84. 2003
    ..To examine the psychometric properties of a newly developed clinician rating scale, the Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA)...
  23. doi Long-term follow-up study of patients with refractory obsessive-compulsive disorder
    Stephen Ross
    Department of Adult Psychiatry, New York University, NY, USA
    J Neuropsychiatry Clin Neurosci 20:450-7. 2008
    ..5% had current OCD and 29.5% had sub-threshold OCD. Almost half reported feeling much improved or very much improved compared to their state prior to treatment with intravenous clomipramine...
  24. doi A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder
    Helen Blair Simpson
    Anxiety Disorders Clinic, New York State Psychiatric Institute, Unit 69, 1051 Riverside Dr, New York, NY 10032, USA
    Am J Psychiatry 165:621-30. 2008
    ..The purpose of this study was to examine the effects of augmenting SRIs with exposure and ritual prevention, an established cognitive-behavioral therapy (CBT) for OCD...
  25. ncbi The social anxiety spectrum
    Franklin R Schneier
    Anxiety Disorders Clinic, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 69, New York, NY 10032, USA
    Psychiatr Clin North Am 25:757-74. 2002
    ..Taking a pluralistic view of the concept of spectrum at this stage may help accelerate our understanding of social anxiety and related disorders...
  26. ncbi Are there reliable neuropsychological deficits in obsessive-compulsive disorder?
    Helen Blair Simpson
    New York State Psychiatric Institute, Unit 69, 1051 Riverside Drive, New York, NY, USA
    J Psychiatr Res 40:247-57. 2006
    ..Whether there are reliable neuropsychological deficits in OCD that can be easily identified in a clinical sample and that contribute to functional impairment remains unclear and requires further study...
  27. ncbi An open trial of fluvoxamine for hypochondriasis
    Brian A Fallon
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, USA
    Psychosomatics 44:298-303. 2003
    ..Significant improvement was also noted on each of the self-report and physician-administered hypochondriasis measures. Fluvoxamine was also well tolerated. A controlled trial is needed...
  28. ncbi Pharmacotherapy of social anxiety disorder
    Carlos Blanco
    Department of Psychiatry, Columbia College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA
    Biol Psychiatry 51:109-20. 2002
    ....
  29. ncbi Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652
    H Blair Simpson
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, New York, USA
    Biol Psychiatry 54:1414-21. 2003
    ..This study examined whether brain serotonin transporter (SERT) availability is altered in OCD using positron emission tomography (PET) and the SERT PET radiotracer [(11)C]McN 5652...
  30. ncbi A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder
    Joshua D Lipsitz
    Department of Psychiatry, Columbia University, Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, USA
    Depress Anxiety 25:542-53. 2008
    ....
  31. ncbi Standard criteria for relapse are needed in obsessive-compulsive disorder
    Helen Blair Simpson
    Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York 10032, USA
    Depress Anxiety 21:1-8. 2005
    ..Standard criteria for relapse are needed in OCD to facilitate comparisons between studies (enabling better treatment guidelines) and to advance research on mechanisms of relapse and relapse prevention...
  32. ncbi The evidence-based pharmacological treatment of social anxiety disorder
    Carlos Blanco
    Department of Psychiatry of Columbia College of Physicians and Surgeons and the New York State Psychiatric Institute, New York, NY, USA
    Int J Neuropsychopharmacol 6:427-42. 2003
    ..Cognitive-behavioural therapy may also be a helpful adjunct or alternative...
  33. ncbi Maternal mental representations of the child in an inner-city clinical sample: violence-related posttraumatic stress and reflective functioning
    Daniel S Schechter
    Division of Developmental Psychobiology, New York State Psychiatric Institute, Columbia College of Physicians and Surgeons, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
    Attach Hum Dev 7:313-31. 2005
    ..Level of maternal reflective functioning and severity of PTSD were not significantly correlated in this sample. Clinical implications are discussed...
  34. ncbi Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions
    Carlos Blanco
    Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    J Clin Psychiatry 69:1276-80. 2008
    ..The goal of this study was to assess the proportion of community-dwelling adults with major depressive episode (MDE) who would meet eligibility criteria for a traditional efficacy trial in patients with MDE...
  35. pmc Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls
    Jonathan D Huppert
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Depress Anxiety 26:39-45. 2009
    ....
  36. ncbi Use of psychotropic medications for patients with office visits who receive a diagnosis of panic disorder
    Carlos Blanco
    Departments of Psychiatry, Columbia University New York State Psychiatric Institute, New York, New York 10032, USA
    Med Care 42:1242-6. 2004
    ..We sought to examine trends in the medication management of panic disorder from a nationally representative sample of visits to psychiatrists and primary care physicians in office-based practice...
  37. pmc Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder
    Franklin R Schneier
    Anxiety Disorders Clinic, New York State Psychiatric Institute, Unit 69, 1051 Riverside Drive, New York, NY 10032, USA
    Depress Anxiety 26:411-8. 2009
    ..D2 receptors and DAT have not previously been studied within the same GSAD subjects, however, and prior GSAD studies have not assessed dopamine release or subdivided the STR into functional subregions...
  38. doi Ziprasidone monotherapy in bipolar II depression: an open trial
    Michael R Liebowitz
    The Medical Research Network, LLC, New York, NY 10024, USA
    J Affect Disord 118:205-8. 2009
    ....
  39. ncbi A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder
    Randall D Marshall
    New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, USA
    Psychiatry Res 110:219-30. 2002
    ..These biological findings support existing clinical, epidemiologic, family study, and clinical trial findings that distinguish these two disorders as distinct syndromes...
  40. ncbi Pharmacological treatment of social anxiety disorder: a meta-analysis
    Carlos Blanco
    Department of Psychiatry of Columbia College of Physicians and Surgeons, Madrid, Spain
    Depress Anxiety 18:29-40. 2003
    ..Direct comparisons of SSRIs vs. other promising medications deserve consideration...
  41. ncbi Empirical validation and psychometric evaluation of the Brief Fear of Negative Evaluation Scale in patients with social anxiety disorder
    Justin W Weeks
    Adult Anxiety Clinic of Temple, Department of Psychology, Temple University, Philadelphia, PA 19122, USA
    Psychol Assess 17:179-90. 2005
    ..Support was obtained for the convergent and discriminant validity of the BFNE and BFNE-S, but not the BFNE-R. These results suggest that standard scoring of the BFNE may not be optimal for patients with social anxiety disorder...
  42. ncbi Relations of the factors of the tripartite model of anxiety and depression to types of social anxiety
    Alicia A Hughes
    Department of Psychology, Temple University, Weiss Hall, 1701 North 13th Street, Philadelphia, Pennsylvania 19122 6085, USA
    Behav Res Ther 44:1629-41. 2006
    ..Findings from this study provide a more detailed account of the specific components of the tripartite model that characterize the diversity of symptoms subsumed by social phobia...
  43. ncbi The appraisal of social concerns scale: psychometric validation with a clinical sample of patients with social anxiety disorder
    Luke T Schultz
    Temple University, Philadelphia, PA 19122 6085, USA
    Behav Ther 37:392-405. 2006
    ..It is concluded that the ASC may be useful in the assessment of cognition and cognitive change in patients with social anxiety disorder...
  44. ncbi Factor structure of the Liebowitz Social Anxiety Scale for Children and Adolescents
    Eric A Storch
    Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA
    Child Psychiatry Hum Dev 37:25-37. 2006
    ..This factor structure appears to be a reliable and valid framework for assessing childhood social phobia...
  45. ncbi Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry
    Dan J Stein
    Medical Research Council Unit on Anxiety Disorders, The University of Stellenbosch, Tygerberg, Cape Town, South Africa
    J Clin Psychiatry 63:12-9. 2002
    ..Future work will undoubtedly clarify how genetic and environmental factors interact to fashion the neurocircuitry that mediates anxiety symptoms...
  46. ncbi The factor structure and screening utility of the Social Interaction Anxiety Scale
    Thomas L Rodebaugh
    Adult Anxiety Clinic, Department of Psychology, Temple University, Philadelphia, PA, USA
    Psychol Assess 18:231-7. 2006
    ..Overall, this study provides support for the excellent properties of the SIAS's straightforwardly worded items, although questions remain regarding its reverse-scored items...
  47. ncbi Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale
    Douglas S Mennin
    Department of Psychology, Temple University, Philadelphia, PA 19122 6085, USA
    J Anxiety Disord 16:661-73. 2002
    ..We sought to determine optimal cutoff values for the Liebowitz Social Anxiety Scale (LSAS) total and subscale scores for the diagnosis of social anxiety disorder (SAD) and designation of the generalized subtype of SAD...
  48. ncbi The OCI-R: validation of the subscales in a clinical sample
    Jonathan D Huppert
    University of Pennsylvania School of Medicine, Center for Treatment and Study of Anxiety, 3535 Market St, Suite 600N, Philadelphia, PA 19104, United States
    J Anxiety Disord 21:394-406. 2007
    ..Further research should examine the sensitivity of the specific subscales to treatment effects, and the potential for adding more items to account for other symptom domains of OCD...
  49. ncbi Overview of panic and social anxiety disorders
    Herman G M Westenberg
    Department of Psychiatry, University Medical Centre, Utrecht, The Netherlands
    J Clin Psychiatry 65:22-6. 2004
    ..Panic and social anxiety disorders are often comorbid with other psychiatric disorders. Medication treatment and/or cognitive-behavioral therapy might need to be continued over the long term to prevent relapse...
  50. ncbi Psychometric properties of disability measures among patients with social anxiety disorder
    James P Hambrick
    Department of Psychology, Adult Anxiety Clinic of Temple University, Temple University, Weiss Hall, 1701 North 13th Street, Philadelphia, PA 19122 6085, USA
    J Anxiety Disord 18:825-39. 2004
    ..Although recognition of the importance of disability as a construct has increased in recent years, there has been little examination of the reliability and validity of disability measures...
  51. ncbi The experience of disability and quality of life in social anxiety disorder
    James P Hambrick
    Adult Anxiety Clinic of Temple University, Philadelphia, Pennsylvania 19122, USA
    Depress Anxiety 18:46-50. 2003
    ....

Research Grants20

  1. PHARMACOTHERAPY OF SOCIAL PHOBIA
    Michael Liebowitz; Fiscal Year: 2001
    ..However, two years of additional funding are being requested to complete study enrollment. When completed, this study should substantially enhance our knowledge of effective treatments for social phobia. ..
  2. CBT AUGMENTATION OF SRI PHARMACOTHERAPY FOR OCD
    Michael Liebowitz; Fiscal Year: 2004
    ....
  3. PHARMACOTHERAPY OF SOCIAL PHOBIA
    Michael Liebowitz; Fiscal Year: 1992
    ....
  4. CBT Augmentation of Paroxetine for Social Anxiety
    Michael Liebowitz; Fiscal Year: 2006
    ..It will also increase understanding of the interplay of psychosocial and pharmacological treatment methods and psychological and biological factors in patients' total response to treatment. ..